Nuclidium provides a cyclotron‑produced copper‑61/‑67 radiopharmaceutical platform that combines PET imaging and targeted beta‑therapy within a single chelator‑ligand framework. The matched isotopic pair enables accurate dosimetry, streamlined manufacturing, and lower per‑dose costs, expanding access for nuclear medicine and oncology departments.
Funding
Funding not disclosed
Founders
Product
Problem
Current radiotheranostic agents often rely on separate radionuclides for imaging and therapy, leading to mismatched biodistribution, complex supply chains, and high production costs. These constraints contribute to diagnostic inaccuracies, delayed treatment decisions, and limited patient access to precision oncology solutions.
Solution
Nuclidium’s platform unites Copper‑61 (β⁺ emitter) and Copper‑67 (β⁻ emitter) into a matched diagnostic‑therapeutic pair, enabling seamless transition from PET imaging to targeted radiotherapy within a single molecular framework. The copper isotopes are produced via cyclotron routes that support high specific activity and scalable batch manufacturing, reducing reliance on scarce reactor‑derived radionuclides. Integrated chelation chemistry ensures stable metal‑ligand complexes across diverse tumor‑targeting vectors, improving dosimetry accuracy and therapeutic index. By consolidating production and distribution, Nuclidium lowers per‑dose costs and expands availability to community hospitals and imaging centers. The platform is positioned for regulatory pathways that leverage the diagnostic‑therapeutic linkage to accelerate clinical adoption in precision oncology.
Target Audience
Primary customers are nuclear medicine departments, oncology centers, and diagnostic imaging networks seeking a single, cost‑effective radiopharmaceutical platform for both cancer detection and targeted therapy.
Features
- Copper‑61 PET agents with sub‑nanomolar affinity for validated tumor biomarkers, delivering high‑resolution quantitative imaging for staging and treatment monitoring.
- Copper‑67 therapeutic conjugates delivering therapeutic dose rates comparable to conventional β‑emitters while maintaining favorable half‑life (62 h) for outpatient administration.
- Unified chelator‑ligand architecture that preserves in‑vivo stability across both isotopes, enabling accurate paired‑dose dosimetry and personalized treatment planning.
- Cyclotron‑based production workflow optimized for high specific activity, batch scalability, and reduced reliance on geopolitically constrained reactor supply chains.
- End‑to‑end logistics network, including GMP‑compliant manufacturing, cold‑chain distribution, and integration with hospital radiopharmacy workflows to ensure rapid patient access.